Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

SELL
$0.12 - $0.3 $458,416 - $1.15 Million
-3,820,139 Reduced 74.97%
1,275,215 $153,000
Q4 2022

Feb 13, 2023

SELL
$0.09 - $4.8 $11,424 - $609,302
-126,938 Reduced 2.43%
5,095,354 $525,000
Q3 2022

Nov 14, 2022

BUY
$0.14 - $4.8 $711,809 - $24.4 Million
5,084,354 Added 3685.97%
5,222,292 $794,000
Q2 2022

Aug 09, 2022

BUY
$0.88 - $1.73 $56,292 - $110,666
63,969 Added 86.48%
137,938 $121,000
Q1 2022

May 11, 2022

BUY
$1.14 - $2.09 $84,324 - $154,595
73,969 New
73,969 $92,000
Q4 2021

Feb 14, 2022

SELL
$1.67 - $2.76 $53,413 - $88,275
-31,984 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$2.62 - $3.45 $83,798 - $110,344
31,984 New
31,984 $88,000

Others Institutions Holding VTGN

# of Institutions
1
Shares Held
27.1K
Call Options Held
0
Put Options Held
0

About VistaGen Therapeutics, Inc.


  • Ticker VTGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 206,836,000
  • Market Cap $517M
  • Description
  • VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III d...
More about VTGN
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.